NCT04785612View on ClinicalTrials.gov

Study of RSVpreF Vaccination and RSV Challenge in Healthy Adults

PHASE2CompletedINTERVENTIONAL

Enrollment

70

Participants

Timeline

Start Date

November 10, 2020

Primary Completion Date

April 8, 2021

Study Completion Date

August 16, 2021

Conditions

Respiratory Syncytial Virus Infections

Interventions

BIOLOGICAL

RSVPreF

A single dose of 120 mcg RSVpreF for intramuscular injection

OTHER

Placebo

A single Placebo dose for intramuscular injection to match experimental vaccine

Trial Locations (1)

E1 2AX

Golam Kabir, London

Sponsors

Lead Sponsor

Collaborators (1)

All Listed Sponsors

collaborator

Pfizer

INDUSTRY

lead

Hvivo

INDUSTRY